Table 1.

Exploratory biomarker analysis of IMpassion 130

Biomarker	Number of subjects	HR PFS A + nP vs P + nP	mPFS	HR OS A + nP vs P + nP	mOS
PD-L1 immune cell expression ≥ 1% and < 5% (low)	243/902(26.9%)	0.61 (95% CI 0.46–0.80) p < 0.005	7.4 mo	0.68 (95% CI 0.48–0.94) p = 0.02	22.6 mo
PD-L1 immune cell expression ≥ 5% (high)	125/902 (13.9%)	0.71 (95% CI 0.48–1.05) p = 0.09	9.3 mo	0.76 (95% CI 0.46–1.26) p = 0.29	28.9 mo

A total of 902 patients were enrolled and randomized equally to receive either A + nP or P + nP. 40.8% of patient enrolled in the trial were PD-L1 immune cell-positive, defined as PD-L1-positive immune cells occupying at least 1% of the tumor area as determined by the Ventana SP142 assay. Data from Emens JNCI 2021

HR hazard ratio, A atezolizumab, nP nab-paclitaxel, P placebo, PFS progression-free survival, mPFS median progression-free survival, OS overall survival, mOS median overall survival, PD-L1 programmed death ligand-1, CI confidence interval, mo months